Kimberly Burlison
Head of US Market Access Orchard Therapeutics
Kimberly Burlison is Head of U.S. Market Access at Orchard Therapeutics, where she leads national strategy for payer engagement, reimbursement, and access for the company’s gene therapy portfolio for rare diseases. Her work focuses on partnering with commercial and public payers, advancing value-based agreements, and supporting treatment centers to enable sustainable access to and reimbursement for advanced therapies. With a deep passion for patient-centered care and innovative access solutions, Kim brings a wealth of expertise to the evolving landscape of gene therapy commercialization.
Seminars
- Examining how evolving clinical data, payer expectations and policy shifts are redefining commercial success for advanced therapies
- Understanding how affordability pressures, evidence requirements and real-world delivery constraints are shaping near term and long-term market viability
- Exploring what manufacturers, payers and providers need to prioritize to sustain patient access as pipelines expand into larger and more common indications
Cell and gene therapies offer transformative clinical potential but introduce unique pricing and reimbursement challenges that can delay or restrict patient access. Payers must evaluate therapies characterized by high upfront costs, limited long-term durability data at launch, and small patient populations. Short budget cycles, member churn, reinsurance considerations, public payer constraints, and evolving evidence standards further complicate value assessment and coverage decisions. Treatment centers also face operational and reimbursement risk when delivering high-cost advanced therapies. This workshop provides a practical forum to explore how manufacturers can communicate value credibly, address budget impact concerns, and prepare for real-world reimbursement decision making.
This workshop will gather experts to discuss:
- How to communicate long term clinical and economic value for advanced therapies within payer budget cycles that may span only two to three years
- Framing high upfront costs in ways that strengthen payer confidence despite uncertainty around durability and limited real-world evidence
- Understand how to communicate value to treatment centers managing operational, reimbursement, and site-of-care financial risk when delivering high-cost therapies
- Equip commercial and access teams to support healthcare centres in navigating process bottlenecks such as financial clearance, prior authorization, and revenue cycle risk
